Do transcriptionally silent BCR-ABL cells persist in CML patients in molecular remission after stem cell transplantation?
Moravcová
J
J
Nádvorníková
S
S
Sieglová
Z
Z
Formánková
R
R
Krsková
T
T
Dvoráková
R
R
Brdicka
R
R
D002470:Cell Survival; D002678:Chimera; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology* / Q000628:therapy; D008297:Male; D018598:Minisatellite Repeats; D009360:Neoplastic Cells, Circulating; D014411:Neoplastic Stem Cells / Q000473:pathology*; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D012074:Remission Induction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D014158:Transcription, Genetic
D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl